Free tool
FAERS Monitor: Iyuzeh
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216472 or its brand name (Iyuzeh, Latanoprost). Reports on generic versions are filed under their own applications.
Reports
638
Serious
80
13% of reports
Hospitalization
11
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye irritation153
- eye pain87
- vision blurred61
- ocular hyperaemia57
- intraocular pressure increased55
- drug ineffective39
- product quality issue39
- dry eye33
- eye pruritus32
- foreign body sensation in eyes31
- lacrimation increased27
- headache24
- visual impairment23
- photophobia22
- condition aggravated19
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 16 |
| 2013 | 29 |
| 2014 | 27 |
| 2015 | 51 |
| 2016 | 61 |
| 2017 | 134 |
| 2018 | 48 |
| 2019 | 71 |
| 2020 | 70 |
| 2021 | 31 |
| 2023 | 1 |
| 2024 | 23 |
| 2025 | 46 |
| 2026 | 30 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,521 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| foreign body sensation in eyesSignal | 31 | 161.1 | 114.2 | 4,752 |
| intraocular pressure increasedSignal | 55 | 142.5 | 110.6 | 7,558 |
| eye irritationSignal | 153 | 87.9 | 76.5 | 13,053 |
| eye painSignal | 87 | 50.9 | 41.9 | 4,212 |
| ocular hyperaemiaSignal | 57 | 39.6 | 30.9 | 2,111 |
| photophobiaSignal | 22 | 38.6 | 25.6 | 768 |
| eye pruritusSignal | 32 | 31.4 | 22.4 | 913 |
| lacrimation increasedSignal | 27 | 29.5 | 20.4 | 715 |
| dry eyeSignal | 33 | 21.8 | 15.6 | 636 |
| vision blurredSignal | 61 | 14.7 | 11.5 | 767 |
| product quality issueSignal | 39 | 9.5 | 7.0 | 289 |
| visual impairmentSignal | 23 | 6.1 | 4.1 | 94 |
| condition aggravatedSignal | 19 | 2.1 | 1.3 | 9 |
| headache | 24 | 1.3 | 0.9 | 1 |
| drug ineffective | 39 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.